Marshwinds Advisory Co. reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 41,221 shares of the company’s stock after selling 599 shares during the quarter. Eli Lilly and makes up 1.6% of Marshwinds Advisory Co.’s investment portfolio, making the stock its 22nd biggest holding. Marshwinds Advisory Co.’s holdings in Eli Lilly and were worth $3,392,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in LLY. Waldron LP boosted its position in shares of Eli Lilly and by 46.7% during the 1st quarter. Waldron LP now owns 4,948 shares of the company’s stock worth $415,000 after acquiring an additional 1,574 shares in the last quarter. First Midwest Bank Trust Division boosted its position in shares of Eli Lilly and by 21.0% during the 1st quarter. First Midwest Bank Trust Division now owns 54,373 shares of the company’s stock worth $4,573,000 after acquiring an additional 9,443 shares in the last quarter. Leavell Investment Management Inc. boosted its position in shares of Eli Lilly and by 1.4% during the 1st quarter. Leavell Investment Management Inc. now owns 4,827 shares of the company’s stock worth $406,000 after acquiring an additional 67 shares in the last quarter. Oakworth Capital Inc. boosted its position in shares of Eli Lilly and by 18.0% during the 1st quarter. Oakworth Capital Inc. now owns 6,694 shares of the company’s stock worth $563,000 after acquiring an additional 1,019 shares in the last quarter. Finally, Moloney Securities Asset Management LLC acquired a new position in shares of Eli Lilly and during the 1st quarter worth about $202,000. 75.72% of the stock is owned by institutional investors and hedge funds.

Shares of Eli Lilly and Company (LLY) traded up 0.49% during trading on Wednesday, hitting $82.13. The stock had a trading volume of 736,097 shares. The firm has a market cap of $86.65 billion, a P/E ratio of 35.54 and a beta of 0.34. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72. The firm’s 50-day moving average is $80.84 and its 200-day moving average is $82.02.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 earnings per share. Equities research analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.

WARNING: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/09/20/marshwinds-advisory-co-has-3-39-million-stake-in-eli-lilly-and-company-lly.html.

In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the sale, the insider now owns 124,049,283 shares of the company’s stock, valued at $10,307,254,924.47. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 800,000 shares of company stock worth $66,281,600. Corporate insiders own 0.20% of the company’s stock.

Several research analysts have recently issued reports on the company. BMO Capital Markets reaffirmed a “sell” rating and set a $73.00 price objective on shares of Eli Lilly and in a research report on Friday, August 4th. TheStreet raised Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. Leerink Swann cut Eli Lilly and from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $93.00 to $90.00 in a research report on Wednesday, July 26th. BidaskClub raised Eli Lilly and from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. Finally, UBS AG downgraded Eli Lilly and to a “hold” rating and set a $85.00 target price for the company. in a report on Wednesday, July 26th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $88.27.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.